Divestiture • Life Science

Microbix Biosystems Acquires ImaRx Therapeutics - Urokinase

On September 24, 2008, Microbix Biosystems acquired life science company ImaRx Therapeutics - Urokinase from ImaRx Therapeutics

Acquisition Context
  • This is Microbix Biosystems’ 1st transaction in the Life Science sector.
  • This is Microbix Biosystems’ 1st transaction in the United States.

Explore All 789 Divestiture Life Science Deals - Search the Database Free


M&A Deal Summary

Date September 24, 2008
Target ImaRx Therapeutics - Urokinase
Sector Life Science
Buyer(s) Microbix Biosystems
Sellers(s) ImaRx Therapeutics
Deal Type Divestiture

Target Company

ImaRx Therapeutics - Urokinase

United States
ImaRx Therapeutics - Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs.
Explore More Deals

Browse All 215,262 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Microbix Biosystems

Mississauga, Ontario, Canada

Category Company
Founded 1988
Sector Life Science
DESCRIPTION

Microbix Biosystems, Inc. is a provider of pharmaceutical services.


Deal Context for Buyer #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
Country: United States 1 of 1
Year: 2008 1 of 1

Seller Profile 1

SELLER

ImaRx Therapeutics

Redmond, Washington, United States

Category Company
Founded 1999
Sector Life Science
DESCRIPTION

ImaRx Therapeutics, Inc. is a biopharmaceutical company that has been focused on the research, development and commercialization of therapies for vascular disorders.


Deal Context for Seller #
Overall 1 of 1
Sector: Life Science 1 of 1
Type: Divestiture 1 of 1
Country: United States 1 of 1
Year: 2008 1 of 1